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ABSTRACT 
Clinical trials are research studies that (amongst other things) explore whether a 
medical strategy, treatment, or device is safe and effective for humans. Clinical trials 
are conducted all over the world –including in South Africa- and they form the basis 
from which drugs and solutions to health problems are discovered. During clinical 
trials, human subjects are monitored and data is collected and analysed to reach 
conclusions that leads to possible solutions to the problem being examined.  The 
internet of everything, commonly just referred to as the internet of Things provides 
opportunity to connect everything to the internet. This includes the people, devices and 
everything that may be needed in a clinical research. The prospect of using the Internet 
of Things in clinical trials conducted in South Africa seem to be highly beneficial and 
it is very worthwhile to know if the South African Clinical trial industry is ready for 
such a revolutionary approach. 
The findings of this study strongly suggests that provided fears- such as fears of losing 
jobs to an efficient technology are allayed, most stakeholders in the clinical trial 
industry will be very happy to make use of the Internet of things while conducting 
clinical trials. Although there is a big room for improvement, the facilities and 
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infrastructures available in South Africa should be sufficient to start taking advantage 
of the Internet of things but it is not certain whether the legal framework in existence 
will be enough to cater for the use of the Internet of things. 
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CHAPTER 1  
INTRODUCTION 
1.1 INTRODUCTION 
This chapter gives general information relevant to the whole research. The discussion 
begins with a proper insight to the background of the research. The section after that 
then presented the problem statement before moving on to explain the objectives of 
this research. The scope of the research is then discussed followed by the assumptions 
and limitations of the research.  
1.2 BACKGROUND 
Clinical trial is the approach used by medical researchers to conduct experiments using 
real human beings to find solutions to medical problems of human beings and answer 
questions relating to preventing, diagnosing and treatment of human ailments or 
diseases. Prior to clinical trials, according to The Pennsylvania State University 
(2017:1),”clinicians attempted to answer such questions by generalizing from the 
experiences of individual patients to the population at large. Clinical judgment and 
reasoning were applied to reports of interesting cases. (But) The concepts of variability 
among individuals and its sources were not formally addressed”. With clinical trials, 
it can be said that attention is paid to variability amongst individuals to a large extent 
and thus there is room for better and more effective interventions to be developed. 
Popularity and acceptance of clinical trials have gone through a lot of ups and downs 
mainly because the research is being conducted with human beings and many issues 
such as balancing the benefits derived or derivable from such studies with the level of 
risks to which participants are exposed and ethical issues that stem from the high 
potential for exploitation and maltreatment of especially vulnerable group of people 
such as disabled children, old people, prisoners, terminally ill people and many others 
in similar categories. However, due to improvement in policies, laws, process and 
understanding of the clinical trials, more and more clinical studies are being conducted 
per year. As of March 2017, there are over 230, 000 registered clinical studies being 
conducted worldwide with the majority of them being conducted in the USA. Figure 
1 below shows the percentage of clinical studies being conducted per location and 
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figure 2 shows the number of registered studies over time between the year 2000 and 
2017(the improvement is highly noticeable in less than 20 years!): 
 
 
 
 
 
 
 
 
 
Figure 1: Percentage of Registered Studies by Location 
(Adapted from clinicaltrials.gov, 2017:1) 
 
 
Non-U.S. only (47%) 
 
U.S. only (36%) 
 
Not provided (12%) 
 
Both U.S. and non-U.S. (6%) 
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Figure 2: Number of registered studies over time 
 
The number of registered studies in South Africa in 2012 as shown in Figure 3 is quite 
encouraging with companies such as Quintiles and Parexel taking the lead in the South 
African market. 
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Total number of registered clinical trials in South Africa  
Figure 3: Registered clinical trials in South Africa in 2012 
 
Available statistics on the global market worth of the clinical trial industry is a little 
bit discrepant. While Fassbender (2017: 1) put that the value at $27 billion as at 2014 
and projected that the value will increase to more than 45 billion by the year 2020, 
Pharmsource (2017:1) believes the amount to be spent on clinical trials could reach a 
whopping $72 billion by the year 2020. Whichever way one looks at it, a conclusion 
can be drawn that clinical trial industry is a thriving and growing industry. In South 
Africa, about R2 billion was spent on health related research and development 
activities and about R800million of this amount was spent on clinical trials (Kahn & 
Gastrow, 2008: 1)  
At the core of this thesis is an investigation of how The INTERNET OF THINGS 
(IoT) may be used to improve clinical trials in South Africa thus it is equally important 
to understand the industry of Internet of Everything alongside that of clinical trials. 
The advent of the internet was well lauded by many people who believed that it was 
the best thing to have ever happened to humanity and hitherto, we are still reaping the 
benefits offered by the internet in almost all ramifications of life, be it business or 
personal. The promises of Internet of everything (referred to as Internet of Things in 
this study) on the other hand are overwhelming and the expected benefits surpass all 
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we have ever thought of. In 2011, Evans (2011:1) predicted that about 50 billion things 
would be connected to the internet by the year 2020. Though this figure is now fast 
turning out to be quite unrealistic, the general agreement is still that a lot of things will 
soon be connected to the internet (Nordrum, 2016:1).  According to Postscapes 
(2016:1) “The Global Internet of Things (IoT) market reached USD 598.2 Billion in 
2015 and the market is expected to reach USD 724.2 Billion by 2023. Further, the 
market is projected to register a CAGR of 13.2% during the forecast period 2016-2023 
globally”. Figure 4 below shows a projected increase in the revenue opportunity of the 
Internet of Things from$132 billion in 2014 to $313 billion in 2018. 
 
 
Figure 4: Worldwide internet of things revenue opportunity 
(Adapted from Columbus 2015:1) 
1.3   PROBLEM STATEMENT 
The usefulness of Internet of Things today cannot be over emphasized, the application 
cuts across all spheres of life and several industries including but not limited to 
education, manufacturing, retail, finance and even healthcare. Clinical research deals 
with researches -conducted all over the world including in South Africa- that use of 
human subjects to find solutions to medical or health problems. One however wonders 
the extent to which the promising internet of Things have been applied to clinical 
research particularly in South Africa and it will be very worthwhile to find out the 
reason for slow adoption of application of the Internet of Things to clinical researches 
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and also possibly see how the application of Internet of Things to such clinical 
researches conducted in South Africa can be encouraged. 
 
1.4  RESEARCH OBJECTIVES 
PRINCIPAL OBJECTIVE 
The aim of this research is to determine the level or extent to which THE INTERNET 
OF THINGS (IoT) is presently being used or applied and the possibility of applying 
the Internet of Things while conducting clinical trials in South Africa.  
SUBPROBLEMS 
While looking at the extent to which IoT is presently being used, sub problems include 
the following: 
• To understand the reason behind slow adoption of IoT in clinical trials, why 
is IoT not used if it is not used? 
• To understand if South African Clinical research industry is really ready for 
IoT application 
• To investigate what needs to be done in order  for  South African clinical 
research industry to start applying IoT while conducting the clinical trials 
IMPORTANCE OF THE RESEARCH 
  Relevance to the clinical trial industry  
◦ It will help to understand how to make clinical trials easier through 
application of IoT 
◦ Will provide better understanding of link between clinical trials and IoT 
◦ Monitoring study participants  can be done better 
◦ It can provide vital insight leading to reduction in clinical trial costs 
◦ Add to the already existing body of knowledge relating to the use of 
IoT in clinical research 
 Relevance to researcher 
◦ Acquire more knowledge 
◦ Help to lay foundation for further studies on clinical research and IoT 
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1.5  SCOPE 
The research only investigated the application of IoT to clinical trials in South Africa 
and not focused elsewhere. In the process of doing this, opinions of stakeholders were 
sampled, recorded and analysed but no attempt was made to implement any actual 
application of Internet of Things (IoT) to clinical trials. 
1.6  ASSUMPTION AND LIMITATIONS OF THE RESEARCH 
While the findings of this research could be said to be applicable throughout South 
Africa,-since the samples are drawn from the major stakeholders in clinical research 
in South Africa-such application should be done very carefully bearing in mind the 
nature of the methodology used (focused group). It was assumed that there was no 
difference between clinical research stakeholders in different parts of South Africa as 
the research was mainly based on stakeholder resident in the Free State province of 
South Africa concerning the way they do their jobs and how they feel about IoT and 
application of IoT to clinical research. 
The findings of this research is not expected to be applied outside South Africa in any 
way unless the political, economic and technological conditions of such country is 
highly comparable to what obtains in South Africa. 
Also strong attention is drawn to the fact that the focus group method was used and 
that only stakeholders in the Free state of South Africa participated but for the purpose 
of this research, location does not really matter since many of the participants- though 
based in the Free state- do sometimes have to carry out their assignments even outside 
the Free State.  
1.7 SUMMARY 
The internet is everywhere and everyone is taking advantage of the benefits of the 
internet to effect improvement wherever possible. The chapter has given a general 
background of the research. The main objective of research is to get a feel of the 
general opinion of stake holders in clinical trials in South Africa about the use of the 
internet of Things. The research is limited to South Africa and no actual 
implementation was done but a sampling of opinion on possibility of using the Internet 
of Things to improve clinical trials. 
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CHAPTER 2  
LITERATURE REVIEW 
2.1 INTRODUCTION 
This chapter provides a review of concepts and theories that form the basis of the 
research conducted. Since the whole research was about the use of Internet of Things 
and its possible application to clinical trials, this chapter attempted a description of the 
concept of Internet of Things, a description of clinical trials and clinical trials with the 
South African perspective. The chapter gives an insight into the various stages of 
clinical trials and the factors that engender motivation and barrier for people to 
participate in clinical trials. Finally, the possible links between clinical trials and the 
Internet of things are duly explored 
2.2 OVERVIEW OF INTERNET OF EVERYTHING (IOE) 
2.2.1 What is the Internet of Everything? 
While it is generally acceptable to define the Internet as the world-wide network of all 
networks where all the computer devices may be interconnected to one another, the 
limitation of the internet lies with the very connection of computer devices together. 
However, the world has evolved to such a level where things or objects not 
traditionally seen as a computer device may function in ways similar to computer 
device, example include a door that can be operated like a computer device to open 
and close automatically or as designed by a computer program.  The Internet of 
Everything is a network which connects everything, everything in this regard include 
people, process, data and things. The people refer to human beings who interact with 
the other components of the network in many ways such as people-to-people (P2P) or 
machine-to-people (M2P). The people may also be at the helm of producing or using 
data, people may be involved with process receiving the right process or sending the 
right process to follow to other people or machines in the network. Process is a 
procedure (to put it lightly) of doing something. The Internet of Everything has the 
necessary processes connected to people, machines and data. The data is simply the 
data generated or necessary for the task at hand while things refer to every other things 
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such as machines, animals and other non-living things that we interact with on daily 
basis like cars and so on (Ali, 2015:15-17) 
 
2.2.2 How is the Internet of Everything different from the Internet and the 
Internet of Things? 
The internet is a worldwide network of networks which include computer devices, the 
Internet of Things is an extension of the internet in that it is an internet but other things 
that are not computers are also connected and the Internet of Everything is even a 
further extension of the Internet of Things. While Internet of Everything connects 
everything which include people, data, process and things to the internet, the Internet 
of Things connects just things (objects) to the Internet, these are objects such as cars, 
fridges, doors or any of the things that are traditionally not computers. Though one 
may naturally think the communication type possible with internet of things will be 
machine-to-machine but the internet of things goes beyond machines and that is why 
it is also called the internet of Objects (Ali, 2015:15-17) Internet of everything can in 
any way be seen as a massive improvement on Internet of Things as described above, 
Internet of things is a single technology transition but internet of everything is made 
up of multiple transition of technologies. Internet of Things is embedded in Internet of 
Everything (Cisco, 213:1). 
It is very important to mention that people loosely use the term Internet of Things (IoT) 
and Internet of Everything (IoE) interchangeably. More often than not, when they talk 
about IoT they actually mean IoE but for the purpose of this report, IoT and IoE will 
be treated as different based on the distinction explained above. However, from now 
onward in this report, only the term Internet of Things (IoT) will be used but the 
definition attached to the term IoT is the definition given for IoE. In other words, the 
researcher has decided to go with the popular usage where people use the Internet of 
Things but actually are referring to the Internet of Everything. So the rest of the thesis 
will only mention Internet of Things (IoT) and every time that is mentioned, we 
actually mean the Internet of Everything which is a connection of people, data, process 
and things to the internet. 
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2.3 CLINICAL TRIALS 
2.3.1 What are clinical trials 
According to National Heart, Lungs and Blood Institute, “Clinical trials are research 
studies that explore whether a medical strategy, treatment, or device is safe and 
effective for humans. These studies also may show which medical approaches work 
best for certain illnesses or groups of people. Clinical trials produce the best data 
available for health care decision making.”(U.S National Library of Medicine 2008:1). 
Clinical trials can also be described as special kinds of experiments where the objects 
of the study are subjected to pre-determined manipulations aimed at achieving a 
predictable expected result (Hansson, 2014:42). The objects of study in clinical trials 
are human beings, usually patients that volunteer to take part in the study, this makes 
clinical trials a lot more delicate kind of experiment where a lot of caution need to be 
exercised. Clinical trials are experiments where the manipulations done are treatments 
and the expected outcome is such that the ailment is cured or the patients get better. 
The experiment performed via clinical trials must be very repeatable in order for the 
trial to be seen as successful, this is because the aim of the trial is probably to find cure 
or treatment for a medical condition. It will therefore be futile if the same results could 
not be achieved with similar objects under the same condition. For example, if we have 
two patients with diabetes of the same age, and weight and other conditions are similar, 
administering a certain medication is expected to produce the same kind of effect or 
else such medication cannot be relied on in actual practice of treating the disease. 
(Hansson, 2014:42-43). It is also important to add that clinical trials are “action-
guiding” experiments as against being epistemic experiments. Action guiding 
experiments are experiments that satisfy the following two criteria (Hansson, 2014:42-
42): “(1) the outcome sought after should be aligned towards reaching some desired 
goals of human action.” 
“(2) The interventions studied should be potential candidates for being performed in a 
non-experimental setting in order to achieve that goal.” 
The underlining spur to conduct action guiding experiment is the actual need to find 
solution to the problem and the experiment is not academic in nature (Schiaffonati: 17) 
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2.3.2 Stages of clinical trials 
Clinical trials are conducted in different stages based on the aim and objectives of such 
trials. These stages are called phases and we have phase I, phase II, phase III and phase 
IV.  In Phase I, a small group of people is used to test a new treatment to see things 
such as how it works, the range of dose to use depending on patients, possible side 
effects, the actual effectiveness of such drug or treatment and if it is safe for human 
use. Researchers test a new drug or treatment in a small group of people for the first 
time to evaluate its safety, determine a safe dosage range, and identify side effects (U.S 
National Library of Medicine 2008:1). In Phase II, the researcher now proceed to test 
the treatment on a larger group of people, the aim here is to confirm that the treatment 
is effective and to establish if it will still be safe for use(U.S National Library of 
Medicine 2008:1). In Phase III, the treatment is now given to large groups of people 
and this time the aim is to be sure that the treatment is effective, to concentrate a bit 
more on the side effects and determine the actual cause and parameters around those 
side effects and to compare the treatment compare to other treatments that are used for 
the same medical condition. Lastly in phase III, all necessary information needed in 
order to use the treatment safely are collected (U.S National Library of Medicine 
2008:1). The last stage is Phase IV, which can be said to be a post marketing stage. In 
phase IV, researchers conduct the research after the treatment have been marketed and 
used by people generally. The purpose is to establish the effect of the treatment on 
various populations of people. For instance, some side effects hitherto not discovered 
may now surface (some of these may be due to long-term usage of the treatment) (U.S 
National Library of Medicine 2008:1). 
2.3.3 Barriers and motivation for participating in clinical trials 
2.3.3.1 Barriers to participation in clinical trials 
The very sensitive nature of clinical trials may be the very reason why people are 
reluctant to take part in them. Some of the main reasons for shying away include fear 
and lack of trust in the research or the researchers. Fear may be ascribed to lack of 
knowledge, wrong beliefs about the safety of the procedures used in conducting 
clinical trials and also the inconvenience, discomfort or pains anticipated by the 
participants. In a study conducted by Owens, Jackson, Thomas, Friedman, and Hébert, 
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(2013:4), it was discovered that African Americans are less receptive to participation 
in clinical research than their white counterparts. Apart from the reasons already 
mentioned, other reasons stated by the participants include lack of health insurance to 
fall back on if something goes wrong as a result of participation in such trials and lack 
of time for the commitment required for participation in clinical trials. It may not be 
wrong to believe the same reasons mentioned here are applicable to South Africans as 
well. 
 
2.3.3.2 Motivators for participation in clinical trials 
Having talked about the barriers to participation in clinical trials, it is equally important 
to mention if there is any, the factors that can motive people to participate in clinical 
trials. According to Owens, Jackson,  Thomas, Friedman,  and Hébert,  (2013:4), 
factors motivating people to participate in clinical trials include “money, assurance of 
safety while participating in the clinical trial, education regarding clinical trial 
procedures, the potential for the research to benefit someone in their family or 
community, encouragement from peers, and free healthcare”. 
 
2.4 THE LINK BETWEEN INTERNET OF THINGS AND CLINICAL TRIALS 
If it is believed that the Internet of Things (IoT) will bring revolutions to organizations 
across industries such as Education, manufacturing, transport, retail and other 
industries, then the same can be said of the health industry. If the traditional Internet 
of Things is half as powerful as it is claimed to be, then one can only start to imagine 
the level of advancement that Internet of Everything (IoE) brings! 
In health generally, benefits of the use of the Internet of things or the Internet of 
Everything cannot be overlooked in anyway. Lot of interesting changes are envisaged: 
the number of cell phone users is expected be more than 5 billion by 2019; 100 billion 
devices are expected to be connected by 2025 and an impact of more than 11 trillion 
is anticipated on the world economy (Rose, Eldridge & Chapin, 2015:1: Iqbal, 2016:1). 
One may be right to say Health industry stands to gain a lot (maybe more than the 
other industries) with the advent and application of IoT for the use of IoT is estimated 
to “be worth $117 million by 2020”(Iqbal, 2016:1).  
Clinical trials are very complex research to conduct for many reasons such as the fact 
that the objects of the experiments are human beings who may actually be sick or 
having a medical problem to which solution is sought. Some of the studies include 
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many patients who are not close to one another or to the researchers, processes need 
to be followed and data need to be generated, collected and analyzed. The benefit 
brought by IoT in clinical trials include remote monitoring and remote gathering of 
data. These can be done by using wearables and the mobile phones (mHealth) among 
other available technologies. MHealth is simply administering medical care through 
the use of mobile phones while wearables are devices that the user can wear. These 
devices have embedded sensors that assists in gathering necessary data on regular basis 
(Iqbal, 2016:1). 
2.5 SUMMARY 
This chapter looked at various underlying theories and concepts that motivated the 
research. Clinical trials are studies conducted using human subjects with the aim of 
finding solutions to health issues. The Internet of everything, commonly called the 
internet of things connects everything to the internet and thus promises a great benefit 
when applied in health sector.  
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CHAPTER 3  
RESEARCH METHODOLOGY 
3.1 INTRODUCTION 
As mentioned earlier, the main aim of this research was to see the extent to which 
Internet of things is applied to clinical trials and to get a view of the reasons behind 
the reluctance in the use of the Internet Of Things while carrying out clinical trials in 
South Africa and to see if there is a possibility of encouraging the use of Internet of 
Things in Clinical trials conducted in South Africa. The researcher use qualitative 
method while carrying out this research.  
Although they were many studies conducted into the application of the Internet of 
Things to healthcare (Bui & Zorzi, 2011; Islam et al 2015), it is very hard to come 
across one conducted with specific consideration of the South African perspective. 
Hence this research attempted to fill the gap and pave way for more of such studies in 
South Africa. 
The following sections deal with the paradigm, the research strategy and methodology 
used in this research.  
3.2 PARADIGM AND METHODOLOGY 
For a very long time, positivist paradigm has dominated the studies conducted in 
healthcare (Burns and Grove, 2001). The positivist paradigm is the backbone of 
quantitative research and it is of the view that human behaviours could be studied as 
reality that can be seen as observable, objective-as against being subjective- and that 
these behaviours can be quantified. This means that human behaviours could be seen 
as “ordered, rational, and logical” and that obtained data could be collected and 
analysed in a strict controlled manner (Reiners, 2012: 1). 
However this study wanted to allow for the subjective views of the stakeholders in 
clinical trial industry in South Africa to be taken into consideration. The possibility of 
multiple -not absolute- truths which emanates from the constructivist paradigm is 
employed. Constructivism form basis for qualitative research where participants are 
seen in a more naturalistic view (Labonte, & Robertson 1996:434) where human 
realities are constructed based on previous experience and prone to different 
interpretations as perceived by different people. An example is a temperature of 15 
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degrees Celsius which is perceived as warm by somebody from Finland and the same 
temperature is perceived as cold by someone from Nigeria. In line with the objectives 
of this research, which is to gain an understanding from stakeholders of clinical trials 
in South Africa about the application of Internet of Things to clinical trials conducted, 
the researcher deemed it highly appropriate to use a qualitative approach. 
3.3 METHODS  
The Focus group method was used in conducting this research. Focus group is a 
research method based on the qualitative approach, it can be described as “a type of 
in-depth interview accomplished in a group, whose meetings present characteristics 
defined with respect to the proposal, size, composition, and interview procedures. The 
focus or object of analysis is the interaction inside the group. The participants influence 
each other through their answers to the ideas and contributions during the discussion. 
The moderator stimulates discussion with comments or subjects. The fundamental data 
produced by this technique are the transcripts of the group discussions and the 
moderator's reflections and annotations” (Freitas, Oliveira Jenkins and Popjoy, 
1998:2). Prior to the use of focus group, qualitative studies used participants 
observations and interviews but focus group method serves as a combination of these 
two previous methods with benefits such as saving time and saving costs(Morgan, 
1996:8-10).  According to Nagle and Williams (2013:1-12), an effective focus group 
research consists of a process of 5 stages.  These are briefly described below: 
 
 
STAGE 1- STUDY PURPOSE 
This is the stage where the purpose of the research is defined, it is very important to 
get this stage very right as it will hugely affect all other stages that follow.  A focus 
group can be for exploration, program development, systematic research or evaluation 
(Nagle & Williams 2013:3).  In this study, the purpose was for exploration. The 
researcher only wanted to find out from the participants about their views on the 
application of Internet of Things to clinical trials. 
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STAGE 2-METHODOLOLY 
The methodology stage of focus group has two aspects; conceptualisation and logistics 
(Nagle & Williams 2013:3) Conceptualisation involves the definition of population 
and sampling. These are further discussed in details in the sampling section below. 
The methodology stage is also the stage where the questions are developed and the 
logistics planned. For this research, the following questions were developed and used 
for the focus group:  
 
1. TO WHAT EXTENT DO YOU THINK IOT IS APPLIED TIN CLINICAL 
TRIALS CONDUCTED IN SOUTH AFRICA? 
2. HOW DO YOU THINK IOT CAN IMPROVE CLINICAL TRIALS IN 
SOUTH AFRICA 
3. WHY DO YOU THINK THERE HAS BEEN SLOW ADOPTION OR 
INCORPORATION OF IoT IN CLINICAL TRIALS IN SA? 
4. IF IT WAS ONLY UP TO YOU, WOULD YOU USED IoT IN YOUR 
REASEARCH RIGHT NOW, WHY? 
5. WHY WOULD YOU SAY SOUTH AFRICAN CLINICAL RESEARCH 
INDUSTRY IS READY OR NOT READY FOR INCORPORATION OF 
IoT IN THE TRIALS TO BE CONDUCTED FROM NOW?(DO WE HAVE 
WHAT IT TAKES?) 
6. WHAT DO YOU THINK NEEDS TO BE DONE FOR CLINICAL TRIALS 
IN SOUTH AFRICA TO TAKE PROPER ADVANTAGE OF IoT 
It should be noted that all of the above questions are open ended questions, close-
ended questions will completely defeat the purpose of any focus group interaction. 
In addition to defining the population and sample and developing the appropriate 
questions, the methodology stage is also the stage where logistics are planned. 
Nagle and Williams (2013:4) suggested that the following tasks-with the suggested 
time frame may be needed in order to conduct an effective focus group:  
 
“Develop the Study Purpose        6-8 Weeks 
Identify the Participants         6-8 Weeks 
Develop Participant Contact List    6-8 Weeks 
Select the Facilitator    4-5 Weeks 
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Question Development     4-5 Weeks 
Develop the Script     4-5 Weeks 
Pilot test questions and script. Revise as necessary  4 Weeks 
Obtain IRB Approval    dependent on institution 
Identify and reserve focus group site   4 Weeks 
Invite Participants     3-4 Weeks 
Verify Invitation to Participants by Phone 2 Weeks 
If there are multiple facilitators, 
Conduct a training on the script to promote study reliability 2 Weeks 
Finalize Room Arrangements    1 Week 
Reminder Call to Participants    2 Days 
Organize all Needed Materials   2 Days” 
(Nagle and Williams 2013:4) 
 
STAGE 3 FACILITATION 
The third stage is facilitation. This is a very important stage as facilitation can make 
or mar a focus group. Proper facilitation involve knowing when to pause, probe, 
use non-verbal communication, take different personalities of the participants into 
consideration and properly forming and enforcing rules that govern the activities 
of the focus group (Nagle and Williams 2013:6-8). 
In this particular study, owing to the fact that the researcher was working alone, a 
member of the group has been asked to assist with facilitation thereby giving the 
researcher ample opportunity to take notes and to observe non-verbal 
communication during the course of the focus group activities. It also came with 
an advantage of members of the focus group owning the focus group and it 
enhanced a much freer participation. The volunteering member was briefed before 
the focus group and the researcher only had to come in if the discussion seem to 
be veering off the main focus. 
 
 
STAGE 4 ANALYSIS 
This is the stage where all the focus group discussion are brought together into 
“manageable form” that can be used to write a report (Nagle and Williams 2013:6-
8). This stage sets the pace for the next stage which is report writing. It is in this 
26 
 
stage that each question is looked at and the responses to the questions are 
organised in such a way to make it easy to write a meaningful report. 
 
STAGE 5 REPORT 
This is the stage where the actual report of the whole focus group discussions is 
written (Nagle and Williams 2013:6-8). Factors which must be considered while 
writing the report include the following (Nagle and Williams 2013:6-8): 
 
The Audience: It is very important to know the audience for which the report is 
intended, that will also help in shaping the style and the language of the report. Or 
this study, the audience include all the stake holders in clinical research and those 
that can benefit from clinical research (including the Government) 
The style of writing: the style should be decided based on the audience and other 
factors, the researcher should consider either writing in the narrative style of bullet 
points. Bullet-point style is much more suitable where the audience will not have 
much time to read and will like to just get to the points but details may be missed. 
The narrative style on the other hand is more detailed but time consuming. In this 
study, the report has been written in the narrative style. 
 
Sequence of report: The report could either be written according to theme or 
according to the questions. In this study, the report has been written on a question 
by question sequence  
 
Participant Information: It is very important to include the participants’ 
information in the report. The report in this thesis include details such as the 
number of people that participated, number of women, the number of men, and the 
different capacities (such as clinical researcher, project manager) in which they 
participated. 
Use of quotes from focus groups: one of the best way to write a very effective 
report from focus group activities is by using quotes directly taken from 
participants of the focus group discussions. 
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Summary: the last step to take in writing report is to give a summary of “how the 
focus group results align with the focus group purpose” (Nagle and Williams 
2013:6-8) 
3.4 SAMPLING 
Because focus group method is used, probability sampling or random sampling are 
automatically excluded as they do not go in line with the focus group method. While 
the researcher tried  to make sure that the composition of each focus group was 
balanced (by having mixed stake holders), it should be noted that striking such balance 
was so difficult since the study actually used convenience sampling- which proved to 
be more appropriate and more practicable in this study. The population, from which 
the samples are drawn, in this case includes stakeholders in clinical research in South 
Africa, these include clinical Site Study Coordinators, Study Nurses, and Laboratory 
Clinical Technologists 
 Laboratory Technicians, Administrative Assistants, Data Administrators, study 
project managers and Recruitment Officers. Sampling is done from staff of three major 
clinical research companies in Bloemfontein South Africa. Three focus groups were 
conducted for this study and each focus group consisted of between 8 to 13 
participants. The subjects were selected based on availability and willingness to 
participate in the focus group activities. 
3.5 DATA 
3.5.1 Data collection  
Since the focus group method is used, data is collected in all focus group discussions 
through audio recording and by note takings done by the researcher. Some important 
no-verbal data are collected through observation of body language and recorded in the 
notes taken by the researcher.  
3.5.2 Data validity and reliability  
Reliability is a very important factor in any study, it is the extent to which a 
measurement taken is consistent, precise and reproducible.  (Flom, 2017:1; 
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Professional Testing Inc, 2006: 1) When the focus group method is used, attention 
should be paid to reliability because of the fact that human beings are most unlikely to 
respond in the same way to a particular question.  Even the same people may respond 
to a particular question in slightly different manners if asked at different times thus big 
chances are that another focus group consisting of similar but different people may not 
necessarily give similar answers to the same question. Flom (2017:1) is of the opinion 
that reliability can be improved if “the moderator is highly trained and Questions are 
relatively specific” In line with Flom (2017:1) as quoted above, the researcher, while 
conducting this study, took every caution to stick to the questions as written down in 
order to foster reliability. 
 
Validity deals with determining whether or not the study actually measures what it is 
supposed to measure. A data is valid if it is a measure of what it is intended to measure. 
(Flom, 2017:1; Professional Testing Inc, 2006: 1)  For example, if one wants to see 
how good a set of Finish students are in mathematics and a mathematics test is set up 
in English language without considering whether the students understands English 
language to the extent of taking a mathematics set up in English language, the data 
from such a test may not be seen as valid.  Focus group is said to have a strong validity 
(Flom, 2017:1) since the moderator is present at the time of focus group discussions 
and the moderator ensures that participants are actually talking about what they should 
be talking about. 
3.5.3 Data Analysis 
Analysing data is very much as important as generating or collecting the data. It is 
through the analysis of the collected data that meaningful conclusions can be drawn. 
In this study, the generated data found in the notes and the recorded audio was 
reviewed at the end of each focus group discussions. These reviews provided an insight 
into the key issues derived from the voiced out opinions of the participants and non-
verbal information observed by the researcher. 
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3.6 SUMMARY 
This chapter looked in depth at the research methodology used in conducting this 
research. As against the positivist paradigm, the constructivist paradigm-which allows 
for multiple truths- was used and the actual method of focus group was used in line 
with the qualitative nature of this study. There are 5 stages involved in a focus group 
study; these are study purpose, methodology, facilitation analysis and the report stages. 
Data for this was sampled from a population that include various stakeholders in the 
clinical research industry in a convenient manner based on the availability of the 
research participants. 
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CHAPTER 4  
RESULTS 
4.1 INTRODUCTION 
One of the most important aspects of conducting a study is being able to come up with 
the result of such a study. In this section, the result is presented and analysed and some 
conclusions are then drawn from the analysed result. Also the ethical consideration 
taken are discussed in this section. 
4.2 RESULTS AND ANALYSIS 
4.2.1 Participant composition  
Three (3) focus group discussions were conducted altogether in this research. The first 
group was made up of 8 participants, the second group was made up of thirteen (13) 
participants and the third was made up of ten (10) participants. This brings the total 
number of participants to thirty one (31) and out of the 31 total participants, 39% (n= 
12) were male while about 61% (n= 61) were females. The exact composition of the 
three groups are as shown in the table below: 
 
Table 1: Participants composition 
PARTICIPANT 
TYPE 
GROUP 1 GROUP2 GROUP 3 TOTAL 
Study 
coordinators 
2 1 2 5 
Recruitment 
Officers 
3 2 3 8 
Laboratory 
personnel 
0 1 1 2 
Study Nurses 0 6 3 9 
Study Project 
managers 
1 1 1 2 
Database 
Administrators 
1 2 0 2 
31 
 
Administrative 
assistance 
1 0 0 1 
TOTAL 8 13 10 31 
 
 
 
 
 
 
 
Figure 5: Participant's summary 
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Figure 6: Group 1 summary 
 
 
Figure 7: Group 2 summary 
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Study Nurses Study Project managers Database Administrators
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Figure 8: Group 3 summary 
 
The focus groups lasted between 45 to 85 minutes. The first few minutes were used 
for introduction and a brief overview of the background and purposes of the focus 
group. It is interesting to note that the participants in all 3 focus groups held 
preferred to allow taping of the proceedings of the focus groups after introductions 
have been made. The researcher on each occasion arranged with one of the 
participants to co-facilitate the focus group in order to give more room for proper 
record taking and for free and fair participation. The co facilitator then proceeded to 
open discussion on a question by question basis while the researcher recorded and 
help to smoothen discussions where necessary  
 
4.2.2 Results and General observations 
From the focus group discussions and questions, six different themes could be 
identifies these include 
1. Present usage of IOT in clinical trial in South Africa 
2. Possible benefits of using IOT in clinical trials in South Africa 
3. Causes of slow adoption of IOT in clinical trials conducted in South Africa 
4. Willingness of stakeholders in using IOT while conducting clinical trials 
5. Readiness of South African clinical research industry in using IOT in clinical 
trials  to be conducted 
6. Actions to be taken 
20 %
30 %
10 %
30 %
10 % 0 %
GROUP 3
Study coordinators Recruitment Officers Laboratory personnel
Study Nurses Study Project managers Database Administrators
Administrative assistance
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In line with Bree and Gallagher (2016:2813-2818), the researcher used Microsoft 
Excel to process and analyse the data obtained from the focus group discussions. The 
data is processed based on the themes and the questions asked. Afters series of 
processing and reduction, the researcher came up with the summary on the following 
table: 
 
Table 2: Obtained data summary 
S/N THEME/QUESTION SOME SELECTED  
COMMENTS FROM 
WHICH KEY 
POINTS ARE 
DERIVED   
KEY POINTS  
1  
THEME 1: PRESENT 
USAGE OF IOT IN 
CLINICAL TRIAL IN 
SOUTH AFRICA 
 
QUESTION: TO WHAT 
EXTENT DO YOU 
THINK IOT IS APPLIED 
TIN CLINICAL TRIALS 
CONDUCTED IN 
SOUTH AFRICA? 
NO, WE ARE NOT 
USING IT; 
 
NONE THAT I 
KNOW OF; 
 
NOT AT ALL 
NOT YET; 
NOT USED IN ANY 
WAY; 
WE HAVE NEVER 
SEEN IT BEEN 
USED 
 
 
 
 
 
 
 
NOT USED IN 
SOUTH AFRICA AT 
THE MOMENT 
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2 THEME 2: POSSIBLE 
BENEFITS OF USING 
IOT 
 
QUESTION: HOW DO 
YOU THINK IOT CAN 
IMPROVE CLINICAL 
TRIALS IN SOUTH 
AFRICA 
IT’S NOT GONNA 
WORK BECAUSE 
OUR SUBJECTS’ 
INFORMATION 
ARE NOT 
ALLOWED TO GO 
OUT; 
HOW WILL THE 
DOCTOR GET 
HOLD OF THE 
VITALS THAT ARE 
RECORDED? 
 
SO I THINK IT MAY 
AFFECT 
CONFIDENTIALITY 
NEGATIVELY 
BECAUSE 
EVERYTHING IS 
LEFT HERE IN THE 
OFFICE SO  
IT WILL SAVE 
TIME 
IT WILL SAVE 
MONEY 
 
IT WILL HELP TO 
IMPROVE 
PARTICIPATION 
(SOME SUBJECTS 
MAY FORGET 
APPOINTMENT) 
 
IMMEDIATE 
FEEDBACK ON 
SUBJECTS’ 
PROGRESS  
 
USE TIME WELL 
 
ENCOURAGE 
COMPLIANCE 
 
REDUCE STIGMA 
ISSUES 
 
WILL INCREASE 
CONFIDENTIALITY 
IF WELL 
ORGANISED 
 
SAVE MONEY 
 
 
INCRESE DIGNITY 
 
INCREASE 
CONFIDENTIALITY 
 
IMPROVED 
PATIENT/SUBJECT 
MANAGEMENT 
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IT WILL 
ENCOURAGE 
PEOPLE  
 
IT WILL HELP 
WILL ERODING 
STIGMA PROBLEM 
 
 
3 THEME 3: CAUSES OF 
SLOW ADOPTION OF 
IOT 
 
QUESTION: WHY DO 
YOU THINK THERE 
HAS BEEN SLOW 
ADOPTION OR 
INCORPORATION OF 
IOT IN CLINICAL 
TRIALS IN SA? 
NONE OF THE 
SPONSORS HAVE 
CAME UP WITH 
SUCH DEVICE; 
 
LACK OF 
RESOURCES; 
 
 
LACK OF 
INFORMATION; 
 
COMPLETELY 
UNKNOWN IN 
SOUTH AFRICA 
 
THE 
GOVERNMENT 
DON’T HAVE 
BUDGET FOR IT; 
 
GOVERNMENT 
WOULD RATHER 
USE THE MONEY 
LACK OF 
EDUCATION 
(SUBJECT AND 
PROFESSIONAL) 
NOT YET 
INTRODUCED BY 
SPONSORS 
FEAR OF BREACH 
IN 
CONFIDENTIALITY 
 
FEAR OF LOSS OF 
JOBS BY 
PROFESSIONALS 
 
LACK OF 
READINESS ON 
THE PART OF THE 
GOVERNMENT 
 
FEAR OF THE 
UNKNOWN BY 
SUBJECTS 
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TO PROVIDE 
MEDICINES 
 
AVAILABILITY OF 
FUNDS TO 
IMPLEMENT 
 
LAW AND 
LEGISLATIONS 
AVAILABILITY OF 
COLLABORATING 
INFRASTRUCTURE 
AND DEVICES 
4 THEME 4: 
WILLINGNESS OF 
STAKEHOLDERS IN 
USING IOT 
 
QUESTION: IF IT WAS 
ONLY UP TO YOU, 
WOULD YOU USED IOT 
IN YOUR REASEARCH 
RIGHT NOW, WHY? 
YES, IT WILL HELP 
ME A LOT 
NO, WHAT IF I END 
UP WITHOUT A 
JOB 
I WILL USE IT, IT 
WILL GIVE US 
MORE TIME TO DO 
OTHER THINGS 
 
IT WILL HELP 
WITH NON-
COMPLIANT 
PATIENTS 
 
IT WILL ALLOW 
US TO HELP 
PATIENTS BETTER 
 
 
WILL USE IT AS 
LONG AS THERE 
ARE NO RISKS 
 
 
WILLING TO USE 
IT IF IT DOES NOT 
LEAD TO LOSS OF 
JOBS 
 
WILLING TO USE 
IT BECAUSE OF 
THE BENEFITS OF 
SAVING TIME, 
MONEY AND 
CONVENIENCE  
5 THEME 5: READINESS 
OF SOUTH AFRICAN 
YES, WE ARE 
READY;  
 
PEOPLE  ARE 
GENERALLY NOT 
READY  
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CLINICAL RESEARCH 
INDUSTRY 
 
QUESTION: WHY 
WOULD YOU SAY 
SOUTH AFRICAN 
CLINICAL RESEARCH 
INDUSTRY IS READY 
OR NOT READY FOR 
INCORPORATION OF 
IOT IN THE TRIALS TO 
BE CONDUCTED FROM 
NOW?(DO WE HAVE 
WHAT IT TAKES?) 
 
WE ARE READY 
BUT WE STILL 
NEED TO 
FOLOLOW SOME 
PROCESS 
 
WE ARE NOT 
READY BECAUSE 
WE DO NOT HAVE 
EVERYTHING WE 
NEED 
 
WE HAVE WHAT 
IT TAKES TO AT 
LEAST START 
 
WE ARE NOT 
READY BECAUSE 
THE PEOPLE DO 
NOT KNOW 
ABOUT IT YET 
 
 
 
PROFRESSIONALS 
ARE WILLING TO 
TRY IT OUT 
 
 
SPONSORS ARE 
NOT READY 
 
GOVERNMENT IS 
NOT READY 
 
 
 
 
6 THEME 6: ACTIONS TO 
BE TAKEN 
QUESTION:WHAT DO 
YOU THINK NEEDS TO 
BE DONE FOR 
CLINICAL TRIALS IN 
SOUTH AFRICA TO 
TAKE PROPER 
ADVANTAGE OF IOE 
WE SHOULD 
EDUCATE THEM 
SO THEY CAN 
UNDERSTAND 
 
EXPLAIN THE 
BENEFITS TO 
SUBJECTS 
 
EDUCATE THE 
PEOPLE 
 
INVOLVE THE 
GOVERNMENT 
 
INVOLVE THE 
SPONSORS 
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THE 
GOVERNMENT 
NEEDS TO TAKE 
INTEREST 
 
THE SPONSORS 
MUST BE WILLING 
TO PROMOTE IT 
 
 
 
 
 
Results  
The following are deductible, based on the theme, from the focus groups conducted: 
Present usage of The Internet of Things 
The clinical trial industry in South Africa is not in any way presently making use of 
the internet of things in carrying out studies 
Possible benefits 
The stakeholders generally agreed that the use of internet of things will be very 
beneficial if applied to the conduct of clinical studies in South Africa. The possible 
benefits cuts across all stake holders from recruiters to study nurses, project 
managers, Study coordinators, laboratory personnel, database administrators all the 
way to Administrative assistance. Everybody is of the view that the internet of things 
will make a positive difference in terms of time saving, cost saving, effort saving, 
improving confidentiality, higher level of accuracy of lab results, easy updates of 
databases, easier filing and general administration, increasing level of interest to 
participate in studies and improvement in the quality of studies conducted. 
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Slow adoption 
Lack of education (subject and professional) 
The general opinion is that there is lack of awareness of the Internet of things and its 
uses amongst the stakeholders in the clinical trial industry in South Africa. Many of 
the participants involved in the focus groups did not know much about the Internet of 
Things by the time they were approached by the researcher. Those who knew about it 
knew very little and they did not think the Internet of Things could be useful in the 
health sector or in the clinical research industry at all. This is the same situation with 
both professional and the subjects that participate in actual clinical trials, nobody 
seems to know much about the Internet of Things! Thus, lack of awareness is one of 
the major factor contributing to the slow adoption or incorporation of the use of the 
Internet of Things in conducted clinical trials in South Africa. 
 
Not yet introduced by sponsors 
The importance of sponsors in clinical trials cannot be over emphasised. Sponsors 
initiate clinical trials and practically make them happen many times fund the clinical 
trials (Chan, Tetzlaff, Gøtzsche, Altman, Mann, Berlin, Dickersin, Hróbjartsson, 
Schulz, Parulekar & Krleža-Jerić). So one can understand that the drive to use the 
Internet of things in South Africa may not pick up until sponsors are deeply 
interested 
 
Fear of breach in confidentiality 
Some of the participants of the focus group think the use of Internet of things may 
lead to breach in confidentiality and may give room for tampering with the integrity 
of the data collected since data will have to pass through the internet. 
 
Fear of loss of jobs by professionals 
Another identified reason that may contribute to slow adoption is the perceived fear 
of loss of job or loss of relevance by professionals. Some are of the view that using 
the internet of Things may mean that they will not have much to do again and may 
lead to loss of jobs or relevance. For example, a participant mentioned that if 
monitoring the subjects’ vital signs are done automatically through a wearable or 
through an implant, then it will mean she will not have much work to do and the 
employers may see no use for her anymore.  
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Lack of readiness on the part of the government 
Another factor identified is the readiness on the part of the government in especially 
in terms of funding. Participants believe that the government will have to invest into 
the idea in order to be able to fully take advantage of the Internet of Things. 
 
Fear of the unknown by subjects 
Participants in the focus group are mostly of the strong view that the subject used in 
clinical trials may have a real hard time accepting the use of the Internet of Things 
since they are not used to it. Some may be wary for fear of the unknown damage that 
it may pose to their health and that of their family members. It may be very difficult 
to persuade them to use wearables and it may be almost impossible at this stage to 
convince them to use things an ingestible or implants. 
 
Availability of funds to implement 
As mentioned before, incorporation of the Internet of Things into clinical research 
will need an additional funding to implement, wearable, ingestible, implants and 
devices necessary to take full advantage of the Internet of Things. If the sponsors are 
not fully involved and the funders are not ready to invest extra money to make this 
happen, then the adoption of the Internet of Things in clinical research in South 
Africa will just have to wait. 
 
Law and legislations 
Clinical trials make use of human subjects and things can easily get complicated on 
the side of law concerning what is right and what is acceptable. Majority of the 
participants are of the opinion that existing laws may need to be modified or new 
laws may have to be put in place in order to take full advantage of the Internet of 
Things in clinical trials. 
 
Availability of collaborating infrastructure and devices 
Another hindrance mentioned is the availability of infrastructure that will be needed 
in order to take full advantage of the Internet of things in clinical research in South 
Africa. While many participants agree that there are necessary infrastructure in place, 
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most of them believe the infrastructure will need to be improved if clinical trials are 
to take full advantage of the Internet of things. 
 
Willingness of participants to use IOT  
Almost all of the participants expressed a high level of willingness to try out the use 
of Internet of Things if it were up to them. The researcher discovered that those who 
showed hesitations both by saying it and through body language are only being 
careful because of fear of the unknown and mostly fear of loss of job or relevance. A 
participant in one of the focus groups was unequivocal about it, she specifically 
mentioned fear of loss of her job. 
 
Readiness of the clinical research industry 
Many, with the exception of few believe that the clinical research industry in South 
Africa is actually ready to incorporate the use of Internet of Things to clinical research 
conducted. Their views is that lack of readiness is most probably on the side of the 
Government in terms of legislation that will permit the express use of IOT and 
availability of infrastructure such as accessibility of the internet in rural areas in South 
Africa. This needs to be seriously considered if the use of Internet of Things is to yield 
maximum benefits.  
Although more people now have access to the internet in South Africa, Access to the 
internet may still pose a little hindrance.  Statistics SA (2017:5) puts the number at 6 
out of ten. This means  “(59,3%)- of South African households- had at least one 
member who used the Internet either at home, their places of work or study, or at 
Internet cafés. Using any means, more than two-thirds of households in Gauteng 
(72,2%) and Western Cape (68,5%) had access to the Internet while only just over one-
third of households in Limpopo (42,4%) had access to the Internet” (Statistics SA 
2017:5). See the figure below: 
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 Figure 9: Percentage of households with access to the Internet at home 
Figure 9 reflects the percentage of households with access to the Internet at home, or 
for which at least one member has access to or used the Internet by province, 2016 
(adapted from Statistics SA. 2017:50) 
 
 
Action to be taken 
Educate stakeholders: All participants agreed that there is need for proper education 
of all the stakeholders in order to encourage acceptance of the use of IOT. Subjects 
need to know it is not risky and will not affect them negatively, professionals need to 
know that it will not lead to loss of jobs and all involved need to see the benefits. 
 
Increase willingness on the part of study sponsors: While it is very important to 
educate the stakeholders about the potential benefits of the use of the Internet of 
Things in clinical trials, all will be a futile effort if the sponsors- who actually pay for 
studies- are not so interested in using IOT. All of the participants work according to 
the protocols set by the sponsors so it does not matter how much they are willing to 
use the IOT, if the sponsors are not willing, then IOT will not be used. So a way must 
be found to increase the interests of sponsors and funders in making use of the 
Internet of Things in clinical studies conducted in South Africa. 
 
Government buy-in: The government need to be not only convinced that IOT should 
be used, they also need to take active participation to ensure that all necessary 
infrastructure is put in place and that all required legislations are attended to. 
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Although it is possible to start enjoying the benefits of the Internet of Things in 
clinical research in South Africa right now based on the available infrastructure, the 
government will need to make improvement and need to put the proper legislation in 
place before the full advantage can be taken. 
 
General observations  
The participants are very careful and cautious, they all requested that the proceedings 
of the focus groups should only be tapped after introductions have been conducted. 
 
The researcher had to go through a whole lot of bottleneck in order to get permission 
from the companies to allow their workers to participate in the study. The researcher 
found out that most companies are wary and were very concerned that the researcher 
may be trying to change their protocols. 
4.3 ETHICS 
Ethics is a very important factor in research generally but there is even a bigger 
emphasis on ethics in clinical research because aside from the general ethics to be 
adhered to, good clinical practice (GCP) (National Institute for Health Research, 
2008:1) must be strictly followed. Throughout the conduct of this research, good 
ethical practices have been used as the back bone of any action taken. Confidentiality 
and anonymity were given special consideration and no harm came to any participant 
or nature as a result of this research. 
4.4 CONCLUSIONS 
While it is clear that the stakeholders in clinical research in South Africa are not using 
the Internet of Things for now, there seem to be excitement and expectation of the 
possibility of using it in the very near future. Professional are very hopeful that the 
Internet of Things will bring about much needed improvements in the manner in which 
clinical trials are conducted and the quality of the process and the results. However, a 
lot still needs to be considered before such level is attained, the people need to be 
educated, the Government need to be carried along and the sponsors need to be deeply 
involved. There is much need for future research to be conducted in this regard to 
follow up on this research.  
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4.5 SUMMARY 
Data obtained from any study need to be analysed in order to come up with results and 
probably draw conclusions and make recommendations. The data obtained from the 
focus groups were broken down based on the questions and 6 themes were derived. 
These themes include present usage of IoT in clinical trial in South Africa, possible 
benefits of using IoT in clinical trials in South Africa, causes of slow adoption of IoT 
in clinical trials conducted in South Africa, willingness of stakeholders in using IoT 
while conducting clinical trials and Readiness of South African clinical research 
industry in using IoT in clinical trials to be conducted. Final result lead to conclusion 
that the Internet of Things is not yet used but the participants are much willing to try 
it out provided it does not lead to loss of jobs and that the sponsors and the government 
do their parts. 
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CHAPTER 5 
CONCLUSIONS 
The findings of this study strongly indicates that in South Africa at the moment, the 
people involved in clinical studies are not making use of the Internet of Things to help 
in anyway while conducting clinical trials. It is however believed that the Internet of 
Things, if used, promises to bring a whole lot of benefits such as saving cost, saving 
time, improving confidentiality and increased level of accuracy of lab results, easier 
maintenance of databases, easier filing and general administration, increasing level of 
interest to participate in studies and improvement in the quality of studies conducted. 
 
It is noteworthy to say that despite all the attainable benefits of the Internet of Things, 
it is important to be prepared and put things in place in order to properly leverage these 
benefits and a lot of such preparations still need to be done in South Africa. For 
example, stakeholders in clinical research industry still need to be educated about these 
benefits, fears need to be allayed in terms of suspected negative effects on jobs, and 
health of the people. Participants need to know that the risk, if any exists, is minimal. 
Professionals need to be assured that they will not have to lose their jobs due to the 
adoption of the Internet of things in clinical trials.  
 
This study also found that there is a high need to secure a strong buy-in from the 
government in order to take full advantage of the Internet of things. Infrastructures 
need to be in place and proper legislation must be promulgated or improvement to 
existing legislation must be made and all these are impossible if the government is not 
interested. In addition, the research findings indicates that it is highly imperative to 
also get the sponsors and the funders of clinical research in South Africa interested in 
using the Internet of Things. Once the sponsors and funders are interested, the use of 
Internet of Things will feature in the protocols of clinical trials and once this is in the 
protocols, then the Internet of things will have to be used as studies are done according 
to protocols provided by sponsors and or funders. 
 
As a follow up to this research, further studies need to be conducted where a piloted 
clinical trial will make use of the Internet of Things, The piloted study will combine 
the traditional methods used for clinical trials now with the mild introduction of the 
47 
 
use of the Internet of things. Such a study should consider use of wearables and 
implants to monitor subjects and obtain important data such as vital signs while using 
the traditional methods to do all other things. Once several of such studies have been 
conducted with incremental use of the Internet of things in subsequent studies, it will 
gradually reach a level where the Internet of things is fully leveraged in clinical trials.  
 
The overarching summary is that the Internet of Things promises to bring great 
improvements to clinical studies conducted in South Africa but like every good and 
beneficial things, focused steps need to be taken in order to make the benefits a reality, 
such steps include educating the stakeholders, getting the Government interested and 
getting the sponsors and funders interested.  
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